395 related articles for article (PubMed ID: 25531161)
1. Developing therapies for peanut allergy.
Bublin M; Breiteneder H
Int Arch Allergy Immunol; 2014; 165(3):179-94. PubMed ID: 25531161
[TBL] [Abstract][Full Text] [Related]
2. Current Trend in Immunotherapy for Peanut Allergy.
Joo Chan C; Richardo T; Lim RLH
Int Rev Immunol; 2018; 37(6):279-290. PubMed ID: 30638084
[TBL] [Abstract][Full Text] [Related]
3. Current opinion and review on peanut oral immunotherapy.
Deol S; Bird JA
Hum Vaccin Immunother; 2014; 10(10):3017-21. PubMed ID: 25483680
[TBL] [Abstract][Full Text] [Related]
4. Epicutaneous immunotherapy for peanut allergy modifies IgG
Koppelman SJ; Peillon A; Agbotounou W; Sampson HA; Martin L
J Allergy Clin Immunol; 2019 Mar; 143(3):1218-1221.e4. PubMed ID: 30389411
[No Abstract] [Full Text] [Related]
5. Extended boiling of peanut progressively reduces IgE allergenicity while retaining T cell reactivity.
Tao B; Bernardo K; Eldi P; Chegeni N; Wiese M; Colella A; Kral A; Hayball J; Smith W; Forsyth K; Chataway T
Clin Exp Allergy; 2016 Jul; 46(7):1004-14. PubMed ID: 27079163
[TBL] [Abstract][Full Text] [Related]
6. Allergen-specific oral immunotherapy for peanut allergy.
Nurmatov U; Venderbosch I; Devereux G; Simons FE; Sheikh A
Cochrane Database Syst Rev; 2012 Sep; (9):CD009014. PubMed ID: 22972130
[TBL] [Abstract][Full Text] [Related]
7. Peanut Allergy: New Advances and Ongoing Controversies.
Abrams EM; Chan ES; Sicherer S
Pediatrics; 2020 May; 145(5):. PubMed ID: 32303583
[TBL] [Abstract][Full Text] [Related]
8. Loss of allergenic proteins during boiling explains tolerance to boiled peanut in peanut allergy.
Turner PJ; Mehr S; Sayers R; Wong M; Shamji MH; Campbell DE; Mills EN
J Allergy Clin Immunol; 2014 Sep; 134(3):751-3. PubMed ID: 25065723
[No Abstract] [Full Text] [Related]
9. Immunotherapy approaches for peanut allergy.
Kim EH; Patel C; Burks AW
Expert Rev Clin Immunol; 2020 Feb; 16(2):167-174. PubMed ID: 31928251
[No Abstract] [Full Text] [Related]
10. High-resolution epitope mapping by AllerScan reveals relationships between IgE and IgG repertoires during peanut oral immunotherapy.
Chen G; Shrock EL; Li MZ; Spergel JM; Nadeau KC; Pongracic JA; Umetsu DT; Rachid R; MacGinnitie AJ; Phipatanakul W; Schneider L; Oettgen HC; Elledge SJ
Cell Rep Med; 2021 Oct; 2(10):100410. PubMed ID: 34755130
[TBL] [Abstract][Full Text] [Related]
11. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy.
Srivastava KD; Siefert A; Fahmy TM; Caplan MJ; Li XM; Sampson HA
J Allergy Clin Immunol; 2016 Aug; 138(2):536-543.e4. PubMed ID: 27130858
[TBL] [Abstract][Full Text] [Related]
12. Low dose immunotherapy in very young children to treat peanut allergy.
Vickery BP
Expert Rev Clin Immunol; 2016 Dec; 12(12):1251-1253. PubMed ID: 27599211
[No Abstract] [Full Text] [Related]
13. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.
Schneider LC; Rachid R; LeBovidge J; Blood E; Mittal M; Umetsu DT
J Allergy Clin Immunol; 2013 Dec; 132(6):1368-74. PubMed ID: 24176117
[TBL] [Abstract][Full Text] [Related]
14. Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy.
Scurlock AM
Clin Rev Allergy Immunol; 2018 Oct; 55(2):139-152. PubMed ID: 29656306
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy using algal-produced Ara h 1 core domain suppresses peanut allergy in mice.
Gregory JA; Shepley-McTaggart A; Umpierrez M; Hurlburt BK; Maleki SJ; Sampson HA; Mayfield SP; Berin MC
Plant Biotechnol J; 2016 Jul; 14(7):1541-50. PubMed ID: 26801740
[TBL] [Abstract][Full Text] [Related]
16. Blockade of peanut allergy with a novel Ara h 2-Fcγ fusion protein in mice.
Liu Y; Sun Y; Chang LJ; Li N; Li H; Yu Y; Bryce PJ; Grammer LC; Schleimer RP; Zhu D
J Allergy Clin Immunol; 2013 Jan; 131(1):213-21.e1-5. PubMed ID: 23199607
[TBL] [Abstract][Full Text] [Related]
17. Peanut allergens.
Palladino C; Breiteneder H
Mol Immunol; 2018 Aug; 100():58-70. PubMed ID: 29680589
[TBL] [Abstract][Full Text] [Related]
18. Beyond allergen avoidance: update on developing therapies for peanut allergy.
Li XM
Curr Opin Allergy Clin Immunol; 2005 Jun; 5(3):287-92. PubMed ID: 15864090
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the immunologic response to peanut during immunotherapy is often transient.
Gorelik M; Narisety SD; Guerrerio AL; Chichester KL; Keet CA; Bieneman AP; Hamilton RG; Wood RA; Schroeder JT; Frischmeyer-Guerrerio PA
J Allergy Clin Immunol; 2015 May; 135(5):1283-92. PubMed ID: 25542883
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy.
Dupont C; Burks AW; Fleischer DM; Bee KJ; Chainani S; Sampson HA
Expert Rev Clin Immunol; 2024 Jun; 20(6):623-633. PubMed ID: 38323337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
